We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Omnia Biologics and AparnaBio Sign Lentivirus Drug Development Agreement

News   Aug 21, 2009

 
Omnia Biologics and AparnaBio Sign Lentivirus Drug Development Agreement
 
 
Advertisement
 

RELATED ARTICLES

New Cancer Vaccine Ready for Human Trials

News

A new cancer vaccine, comprised of human antibodies fused with tumor-specific protein, is ready to begin human testing.

READ MORE

Team Synthesizes Safer Nonaddictive Analgesics

News

A team has discovered a new class of drugs, capable of relieving pain and reducing fever without the danger of addiction or damage to the liver or kidneys.

READ MORE

Controlled Human Infection Models for SARS-CoV-2 Vaccine Development

News

Infecting some volunteers with COVID-19 may provide valuable insights for future rounds of vaccine testing, but would require very strict controls, argues a group of infectious disease experts in the New England Journal of Medicine.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE